32 completed, 5 recruiting, 4 unknown, 3 terminated. 45 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 45 | Completed 32, Recruiting 5, Unknown 4, Terminated 3, Active not recruiting 1 |
Follow Pneumococcal Infections: new trials by email Literature Review of Pneumococcal Infections trials Research Report on Pneumococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines Pneumococcal Vaccine - Vaccine, Pneumococcal Disease | Phase 4 | Recruiting | University of Alabama at Birmingham | 70 | 2026-07-01 | 2026-08-21 |
| Opportunistic Pneumococcal Immunisation Trial in MALnutrition Pneumococcal conjugate vaccine, Typhoid conjugate vaccine - Severe Acute Malnutrition in Childhood, Pneumococcal Disease | Phase 4 | Recruiting | Nick Fancourt | 214 | 2026-01-16 | 2026-10-08 |
| Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults Early intervention, Delayed intervention - Acute Febrile Illness, Pneumococcal Infections | Phase 4 | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 1052 | 2025-12-17 | 2026-03-30 |
| Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15 PCV15, Streptococcus pneumoniae serotype 3, Placebo - Pneumococcal Disease, Pneumococcal Carriage | Phase 4 | Recruiting | University of Oxford | 106 | 2025-02-24 | 2025-04-15 |
| Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years NVX, PCV20, Placebo - COVID-19, Pneumococcal Infections | Phase 4 | Unknown | Medical University of Vienna | 256 | 2023-03-01 | 2023-03-15 |
| Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine Experimental 23-valent Pneumococcal - Pneumococcal Infections | Phase 4 | Completed | Sinovac Biotech Co., Ltd | 1800 | 2023-02-27 | 2023-09-18 |
| Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People Pneumococcal conjugate vaccine - Pneumococcal Infections | Phase 4 | Active not recruiting | London School of Hygiene and Tropical Medicine | 2882 | 2022-11-27 | 2025-06-04 |
| Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine Experimental 23-valent PPV, Control 23-valent PPV - Pneumococcal Infections | Phase 4 | Completed | Sinovac Biotech Co., Ltd | 1800 | 2022-10-25 | 2023-09-18 |
| A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India 13-valent pneumococcal conjugate vaccine - Pneumococcal Disease | Phase 4 | Completed | Pfizer | 200 | 2022-10-06 | 2024-04-26 |
| A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine Investigational 23-valent PPV, Control 23-valent PPV - Pneumococcal Infections | Phase 4 | Completed | Sinovac Biotech Co., Ltd | 600 | 2021-09-10 | 2022-08-12 |
| Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4 COVAX+PPV23;COVAX+IIV4, COVAX only (1st and 2nd dose), PPV23 for the 1st dose and IIV4 for the 2nd dose - Influenza, Human, Pneumonia, Pneumococcal | Phase 4 | Unknown | China National Biotec Group Company Limited | 1404 | 2021-05-06 | 2021-10-15 |
| Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients ProDiax-23 (PPSV23) - Pneumococcal Infections | Phase 4 | Unknown | Korea University Guro Hospital | 254 | 2021-05-01 | 2021-05-06 |
| Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine, 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine - Hiv, Meningococcal Infections | Phase 4 | Recruiting | Thomas Benfield | 55 | 2021-04-28 | 2021-05-06 |
| Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4 COVAX+IIV4; COVAX+PPV23, COVAX only (1st and 2nd dose), IIV4 for the 1st dose and PPV23 for the 2nd dose - Influenza, Human, Pneumonia, Pneumococcal | Phase 4 | Completed | China National Biotec Group Company Limited | 1133 | 2021-03-10 | 2021-10-20 |
| Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4 IIV4 and PPV23, IIV4, PPV23 - Influenza, Human, Pneumonia, Pneumococcal | Phase 4 | Completed | China National Biotec Group Company Limited | 1224 | 2020-09-11 | 2022-08-02 |
| The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants PCV10, PCV13 - Pneumococcal Infection, Streptococcus Pneumoniae Infection | Phase 4 | Completed | London School of Hygiene and Tropical Medicine | 2100 | 2019-03-21 | 2024-11-12 |
| Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Vaccination with pneumococcal conjugate vaccine (PCV13), Standard Antibacterial Prophylaxis - Multiple Myeloma, Pneumococcal Infection | Phase 4 | Completed | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | 36 | 2018-07-01 | 2022-08-31 |
| Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels PCV13, PPV23 - Pneumococcal Infections | Phase 4 | Completed | Jena University Hospital | 123 | 2017-10-18 | 2023-12-01 |
| Evaluation of PCV Schedules in a Naive Population in Vietnam PCV 2p+1, PCV 3p+0, PCV 1p+1 - Pneumonia, Pneumococcal | Phase 4 | Completed | Nagasaki University | 18652 | 2016-10-01 | 2024-04-19 |
| Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine - Rheumatoid Arthritis, Systemic Lupus | Phase 4 | Completed | Region Skane | 300 | 2016-06-14 | 2023-03-29 |
Showing 20 of 45. Sign in to see all of them.
Pneumonia, Pneumococcal (11) · Influenza, Human (7) · Meningococcal Infections (5) · Pneumonia (4) · COVID-19 (2) · Diphtheria (2) · Tetanus (2) · Acquired Immunodeficiency Syndrome (1) · Arthritis, Rheumatoid (1) · Asthma (1) · Diabetes Mellitus (1) · Febrile Neutropenia (1) · Fever (1) · Hepatitis B (1)
Bacterial Infections (45) · Bacterial Infections and Mycoses (45) · Gram-Positive Bacterial Infections (45) · Infections (44) · Streptococcal Infections (44) · Respiratory Tract Diseases (19) · Respiratory Tract Infections (18) · Lung Diseases (15) · Pneumonia, Bacterial (11) · Pneumonia (10) · Virus Diseases (10) · RNA Virus Infections (9) · Orthomyxoviridae Infections (7) · Gram-Negative Bacterial Infections (5)
Pneumococcal Vaccines (9) · 13-valent pneumococcal vaccine (6) · Heptavalent Pneumococcal Conjugate Vaccine (5) · 23-valent pneumococcal capsular polysaccharide vaccine (4) · PHiD-CV vaccine (3) · 10-valent pneumococcal conjugate vaccine (2) · Influenza Vaccines (2) · 4CMenB vaccine (1) · Acetaminophen (1) · Blood Specimen Collection (1) · Ceftriaxone (1) · Early Intervention, Educational (1) · Hepatitis A Vaccines (1) · Ibuprofen (1) · Levofloxacin (1)
Korea University Guro Hospital (4) · Pfizer (4) · China National Biotec Group Company Limited (3) · Public Health England (3) · Sinovac Biotech Co., Ltd (3) · Wyeth is now a wholly owned subsidiary of Pfizer (3) · London School of Hygiene and Tropical Medicine (2) · University of Oxford (2) · Agence de Médecine Préventive, France (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Fakultas Kedokteran Universitas Indonesia (1) · GlaxoSmithKline (1) · Helsinki University Central Hospital (1) · Hospital Mutua de Terrassa (1) · Jena University Hospital (1)
China (9) · United Kingdom (5) · France (2) · Kenya (2) · South Korea (2) · Spain (2) · United States (2) · Belarus (1) · Burkina Faso (1) · Denmark (1) · Finland (1) · Germany (1) · India (1) · Indonesia (1) · Japan (1)
Elizabeth Coates, PhD (2) · Hee Jin Cheong, MD, PhD (2) · Aleksander V Zhestkov, Professor (1) · Anatoly Uss, MD/PhD (1) · Andrei D Protasov, Professor (1) · Andrew Pollard, FRCPCH, PhD (1) · Anu Kantele, MD PhD (1) · Daniel M Musher (1) · Daniela M Ferreira, PhD (1) · Elizabeth Miller, BSc MBBS FFPHM FRCPath (1)
PMID 14998500, PMID 16567982, PMID 19091990, PMID 19906895, PMID 20010312, PMID 20686433, PMID 21191076, PMID 24086113, PMID 24465570, PMID 24618837, PMID 25785969, PMID 25980426, PMID 26083474, PMID 27239929, PMID 27265450, PMID 27616471, PMID 28173960, PMID 28392142, PMID 28410813, PMID 29017280, PMID 29429807, PMID 29488477, PMID 29561248, PMID 30518331, PMID 32087733, PMID 32418789, PMID 35931636, PMID 37780234, PMID 39330966, PMID 39602629, PMID 39633426, PMID 39756693, PMID 40396505, PMID 41165164, PMID 41265006, PMID 41290307, PMID 42202846